A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors YM BioSciences
- 10 Jun 2017 Biomarkers information updated
- 24 Aug 2016 Last checked against Clinical Trials Registry - India record.
- 30 May 2011 Status changed from recruiting to discontinued.